Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
1don MSN
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback